Year: 2023
Type: article
Study design: Observational Study
Abstract: Access to direct acting antivirals (DAAs) may be associated with reductions in hepatitis C virus (HCV) viremia prevalence among people with human immunodeficiency virus (PWH). Among 3755 PWH, estimated HCV viremia prevalence decreased by 94.0% from 36% (95% confidence interval [CI], 27%-46%) in 2009 (pre-DAA era) to 2% (95% CI, 0%-4%) in 2021 (DAA era). Male sex, black race, and older age were associated with HCV viremia in 2009 but not in 2021. Injection drug use remained associated with HCV viremia in 2009 and 2021. Targeted interventions are needed to meet the HCV care needs of PWH who use drugs.
Language: English
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G2456272280, G2509593258, G2516619799, Optimizing outcomes at the intersection of HIV and mental health: Prediction, precision medicine, and population health, Elimination of HCV and related liver disease among HIV-infected and -uninfected people who inject drugs, G607165691, G9000074434, G9000121099, G9000203738, G9000240911, Ending the HIV Epidemic in Rural America (EHE-RA): Local Interventions, Co-Epidemics, and Social Determinants
OpenAlex ID: W4387324643
